Treat to Target in Inflammatory Bowel Disease

被引：25
作者：
Peter Bossuyt
Séverine Vermeire
机构：
[1] KULeuven–University of Leuven,Department of Gastroenterology, University Hospitals Leuven
[2] Imelda ziekenhuis,Department of Gastroenterology, Imelda GI Clinical Research Centre
来源：
Current Treatment Options in Gastroenterology | 2016年 / 14卷 / 1期
关键词：
Treat to target; Mucosal healing; Biomarkers; MRE; Histological healing; IBD;
D O I：
10.1007/s11938-016-0077-z
中图分类号：
学科分类号：
摘要：
With the expanding armamentarium in IBD the current treatment targets can be reached. By optimally using our drugs we can avoid long-term complications in IBD. For this the therapeutic strategy has to be changed from a clinically driven approach to a target-driven strategy. Currently mucosal healing, normalization of biomarkers, histological healing, and healing on abdominal imaging are proposed targets. Correct phenotyping of the patient before initiation of therapy is mandatory. Once treatment is initiated a continuous re-evaluation with consequent adaptation of the treatment when goals are not (yet) reached is needed. Both escalation and de-escalation should be considered. Drug levels can be used as a guidance to reach these targets.
引用
收藏
页码：61 / 72
页数：11
相关论文
共 380 条
  • [1] Hindryckx P(2014)Clinical trials in luminal Crohn’s disease: a historical perspective J Crohns Colitis 8 1339-50
  • [2] Baert F(2011)Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes—consequences for clinical care Bull NYU Hosp Jt Dis 69 104-10
  • [3] Hart A(2015)Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight Lupus 24 507-15
  • [4] Armuzzi A(2015)Treating to target in axial spondyloarthritis: defining the target and the arrow Expert Rev Clin Immunol 11 691-3
  • [5] Panès J(2004)Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial Lancet 364 263-9
  • [6] Peyrin-Biroulet L(2010)DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis Ann Rheum Dis 69 65-9
  • [7] Castrejón I(2013)Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial Arthritis Care Res 65 1401-9
  • [8] Pincus T(2012)A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch rheumatoid arthritis monitoring registry Ann Rheum Dis 71 845-50
  • [9] Doria A(2011)Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort Ann Rheum Dis 70 611-5
  • [10] Gatto M(2012)Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial Rheumatology (Oxford) 51 686-94
12345678910